Clinical Trials Browser

Breast Neoplasms

HER2-positive Metastatic Breast Cancer

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Non-Small-Cell Lung, Genomic Instability

Salivary Gland Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Salivary Gland Neoplasms

Brain Neoplasms

Urinary Bladder Neoplasms, Lung Neoplasms, Urologic Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Brain Neoplasms, Neoplasm Metastasis

Breast Neoplasms

HER2-positive Breast Cancer

Breast Neoplasms

Breast Neoplasms, Heart Failure

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Advanced Breast Cancer

Breast Neoplasms

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

HER2 Positive Breast Cancer

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Brain Neoplasms

Metastatic HER2-positive Breast Cancer With Brain Metastasis

Colorectal Neoplasms

Colorectal Neoplasms

Breast Neoplasms

Clinical Trials

ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer

ZEPHIR-02

I-SPY

DARWINII

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

PHERGAIN-2

ATEMPT 2.0: Adjuvant T-DM1 vs TH

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

BRIDGET

Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

Opti-HER2

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

ProTarget

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

SCHOLAR-2

ZEPHIR

Decrescendo

T-DM1

PATRICIA II

Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

ROME

TRAEMOS

T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

SAFE-HEaRt

PREDIXIIHER2

TEAL

Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

HER2BAT

KIARA

RESCUE

HERACLES

NATURE